|
Market Closed -
Nasdaq
00:00:00 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 73.44 USD | +3.39% |
|
+4.89% | -10.31% |
| 08-12 | Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating | MT |
| 08-07 | Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.12B | - | - | - | ||
| 80.91B | |||||
| 53.62B | |||||
| 50.13B | |||||
| 47.97B | |||||
| 31.41B |
Select your edition
All financial news and data tailored to specific country editions
